A new dual kinase inhibitor for JAK2 and ABL kinases called ON044580 was recently discovered and was shown to target both imatinib-sensitive and resistant K562 CML cells. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.